CRDL
NASDAQCardiol Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.12-0.01 (-0.88%)
01:45 PM07:45 PM
News · 26 weeks29-17%
2025-12-072026-05-31
Mix1590d
- SEC Filings8(53%)
- Other7(47%)
Latest news
25 items- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cardiol Therapeutics Inc.SCHEDULE 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQTORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m. EDT. A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/eve
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart AssociationResults demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment.TORONTO, ON, May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA").
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramLeading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital.Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.Patient enrollment surpassed 50% in early January and has now reached 75%.Target recruitment is anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the additional clinical sites.MAVERIC builds on pos
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartToronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.Interview Topics:The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditisResults from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditisThe Company's next generation drug, CRD-38, i
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Announces Year-End 2025 Update on OperationsInitiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure.Advanced CRD-38 program, a novel next generation drug intended for use in heart failure and other inflammatory heart diseases, to support an Investigational New Drug ("IND") Application and the initiation of Phase I clinical development.Received U.S. patent allowance broadly protecting CardiolRx™ and CRD-38 for use in the treatment or prevention of an extensiv
- SECSEC Form 40-F filed by Cardiol Therapeutics Inc.40-F - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics to Present at TD Cowen 46th Annual Health Care ConferenceToronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's presentation, as well as a webcast replay will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).About
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart FailureToronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol's lead oral drug candidate, in 109 patients with acute myocarditis using advanced cardiac magnetic resonance (CMR) imaging measures of myocardial i
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form SCHEDULE 13G filed by Cardiol Therapeutics Inc.SCHEDULE 13G - Cardiol Therapeutics Inc. (0001702123) (Subject)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
- PRCardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 MillionToronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canaccord Genuity Corp. (the "Underwriter") acted as sole underwriter and sole bookrunner for the Offering. Pursuant to the Offering, the Company issued an aggregate of 11,423,078 Units at a price of $1.30 per Unit for aggregate gr
- SECSEC Form 6-K filed by Cardiol Therapeutics Inc.6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
CRDL FAQ
6 questionsWhat does Cardiol Therapeutics Inc. do?
Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to...Where does CRDL stock trade?
Cardiol Therapeutics Inc. (CRDL) is listed on NASDAQ.What sector and industry is CRDL in?
Cardiol Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about CRDL?
Cardiol Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2025-06-02. Recent price targets range from $700.00 to $1000.00.What companies are similar to CRDL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CRDL side-by-side with any of them on Quantisnow.How can I track CRDL on Quantisnow?
Quantisnow aggregates Cardiol Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRDL to receive live email and push alerts on every new disclosure.